FDA orders eye-risk warnings on every GLP-1 drug: 6.4 cases per 100,000 patient-years vs 3.8

The Food and Drug Administration is requiring the makers of every GLP-1 receptor agonist, the drug class that includes Ozempic, Wegovy and Zepbound, to add a warning about a rare eye condition to their labels, according to the agency's Drug Safety Communication dated November 9. The condition is non-arteritic anterior ischemic optic neuropathy, or NAION, which can cause sudden, painless vision loss in one eye, including permanent loss. Fox Business reported the order on Tuesday.

What the FDA actually found

The headline number comes from a meta-analysis of 126 randomized trials covering 134,253 patients: 78,217 on GLP-1 drugs and 56,036 on a placebo or another diabetes drug. The FDA counted 15 probable NAION events in all, 10 among GLP-1 users and 5 on placebo, with none among patients on other glucose-lowering drugs.

The gap is 2.6 cases per 100,000 patient-years, or roughly one extra case for every 38,000 years of treatment exposure. That is small in absolute terms, but it comes from only 15 events, so the estimate is imprecise.

The real-world data point in two directions

The FDA also ran a cohort study in its Sentinel system of adults with type 2 diabetes who started a GLP-1 drug or another common diabetes medicine between 2019 and 2024. NAION rates ranged from 26 to 32 per 100,000 patient-years, much higher than in the trials because these patients have the risk factors for it. Against SGLT-2 inhibitors, the GLP-1 hazard ratio was 1.19 with a confidence interval of 0.91 to 1.54, which the agency says is not a statistically significant increase. Against DPP-4 inhibitors, it was 1.43 (1.02 to 2.01), which is.

The FDA says animal data did not identify a mechanism by which these drugs could raise the risk, and that the overlap between NAION risk factors and the people prescribed GLP-1 drugs made reports hard to interpret. Its risk-factor list includes smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. The agency still concluded there is a "potential increased risk," and noted NAION cases have been reported for every marketed GLP-1 product. It also cites a July 2024 JAMA Ophthalmology study of semaglutide as what prompted the review.

What the FDA tells patients and doctors

• Patients should contact a health care professional right away for sudden, painless vision loss in one eye, blurred or missing areas of vision, color distortion or hazy spots, which may show up on waking.
• Anyone who has had a NAION event should talk with their doctor about whether to continue the drug.
• Doctors should refer suspected cases to an ophthalmologist promptly and consider stopping the drug in patients who develop NAION, unless the benefit clearly outweighs the risk.
• The communication does not tell patients without symptoms to stop their medicine.

Why the money side matters

This is a label change, not a recall or a restriction, so nothing about prescribing or coverage changes today. But the class is now one of the biggest drug markets in the world, and a new Warnings and Precautions entry applies to all of it at once. Novo Nordisk's ADRs closed at $41.38 on Monday, per Yahoo Finance data, and have been under pressure all year. We have not seen any company statement on the order, and any effect on prescriptions is unknown. For employers weighing coverage, we covered the Walmart benefits move last month, and Novo's latest results are in our November 4 report.

Sources: U.S. Food and Drug Administration (Drug Safety Communication, November 9, 2026); Fox Business; Yahoo Finance. This is health and market information, not medical or investment advice. Talk to your doctor before changing any medication.